Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM84DP5)

• Drug Name: NGM621 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Geographic atrophy	9B75	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DM84DP5

Molecule-Related Drug Atlas

Drug(s) Targeting Complement C3 (CO3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pegcetacoplan	DM4HQ52	Paroxysmal nocturnal haemoglobinuria	3A21.0	Approved	[3]
Imprime PGG	DMIUA3M	Non-hodgkin lymphoma	2B33.5	Phase 2/3	[4]
POT-4	DMH0LM2	Macular degeneration	9B78.3	Phase 2	[5]
AMY-101	DMS0GA6	Gingivitis	DA0B	Phase 2	[6]
Cysteine Sulfenic Acid	DM4GZUJ	N. A.	N. A.	Investigative	[7]
Ac-I[CV(Bta)QDWGAHRC]T	DM5NMVP	Discovery agent	N.A.	Investigative	[8]
Ac-I[CVWQDWGWHRC]T-NH2	DMDIUK6	Discovery agent	N.A.	Investigative	[8]
Ac-ICVWQDWGAHRCT-NH2	DMPSI26	Discovery agent	N.A.	Investigative	[9]
Ac-I[CV(Bta)QDWGAHRC]T-NH2	DMFLA5T	Discovery agent	N.A.	Investigative	[8]
Ac-I[CV(Bpa)QDWGAHRC]T	DMDFKU3	Discovery agent	N.A.	Investigative	[8]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Complement C3 (CO3)	TTJGY7A	CO3_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04465955) A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD). U.S.National Institutes of Health.
• [2] Inhibition of Complement Factor 3 in Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results. Am J Ophthalmol. 2022 Mar;235:131-142.
• [3] Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
• [4] National Cancer Institute Drug Dictionary (drug id 599816).
• [5] Compstatin: A Complement Inhibitor on its Way to Clinical Application. Adv Exp Med Biol. 2008; 632: 273-292.
• [6] The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Jun;215:108450.
• [7] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [8] Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005 Jan 13;48(1):274-86.
• [9] Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 2006 Jul 27;49(15):4616-22.